{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:40:45Z","timestamp":1791808845540,"version":"4.3.4"},"reference-count":123,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bbcan.2024.189167","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:45:01Z","timestamp":1722973501000},"page":"189167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thymic epithelial tumor medical treatment: A narrative review"],"prefix":"10.1016","volume":"1879","author":[{"given":"Qian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2024.189167_bb0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189167_bb0010","first-page":"395","volume":"43","author":"Multidisciplinary Committee of Oncology, Chinese Physicians Association","year":"2021","journal-title":"Zhonghua zhong liu za zhi [Chinese J. Oncol.]"},{"issue":"9","key":"10.1016\/j.bbcan.2024.189167_bb0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, Thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jtho.2016.08.131","article-title":"Determinants of complete resection of Thymoma by minimally invasive and open Thymectomy: analysis of an international registry","volume":"12","author":"Burt","year":"2017","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0030","first-page":"153","article-title":"Thymomas and thymic carcinomas: prognostic factors and multimodal management","volume":"62","author":"Moser","year":"2014","journal-title":"Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0035","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2009.11.057","article-title":"Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma","volume":"89","author":"Hosaka","year":"2010","journal-title":"Ann. Thorac. Surg."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189167_bb0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189167_bb0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"Berruti","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0055","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The eastern cooperative oncology group, southwest oncology group, and southeastern Cancer study group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J. Clini. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189167_bb0060","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0065","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer lung Cancer cooperative group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J. Clini. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.bbcan.2024.189167_bb0070","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.bbcan.2024.189167_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","article-title":"Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1","volume":"7","author":"Rouquette","year":"2019","journal-title":"Biomark. Res."},{"issue":"18","key":"10.1016\/j.bbcan.2024.189167_bb0085","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in Thymic carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189167_bb0090","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in Thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-Centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.bbcan.2024.189167_bb0100","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189167_bb0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer (Oxford, England : 1990)"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO open"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly","year":"2011","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0125","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaneurol.2016.0603","article-title":"Frequency of synaptic autoantibody accompaniments and neurological manifestations of Thymoma","volume":"73","author":"Zekeridou","year":"2016","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189167_bb0130","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan clinical oncology group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189167_bb0135","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0145","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1759-7714.14847","article-title":"Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors","volume":"14","author":"Xu","year":"2023","journal-title":"Thoracic Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0150","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"15","key":"10.1016\/j.bbcan.2024.189167_bb0160","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol. : Off.J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0170","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0175","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","article-title":"A prospective phase II study of cisplatin and Cremophor EL-free paclitaxel (Genexol-PM) in patients with Unresectable Thymic epithelial tumors","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0180","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann. Oncol. : Off.J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0190","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A phase II study of Pemetrexed in patients with recurrent Thymoma and Thymic carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.bbcan.2024.189167_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2019.09.015","article-title":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","volume":"137","author":"Hellyer","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"20","key":"10.1016\/j.bbcan.2024.189167_bb0200","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1002\/cam4.3385","article-title":"Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma","volume":"9","author":"Okuma","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2024.189167_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2019.10.016","article-title":"Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203","volume":"139","author":"Tsukita","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0210","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan clinical oncology group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0220","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"10 Suppl 4","key":"10.1016\/j.bbcan.2024.189167_bb0230","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"25","key":"10.1016\/j.bbcan.2024.189167_bb0240","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189167_bb0245","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0250","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189167_bb0255","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"10 Suppl 4","key":"10.1016\/j.bbcan.2024.189167_bb0260","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2024.189167_bb0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0275","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189167_bb0280","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cncr.33990","article-title":"Resound trial: a phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy","volume":"128","author":"Perrino","year":"2022","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.bbcan.2024.189167_bb0285","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0290","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12916-022-02361-w","article-title":"Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0300","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0305","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tips.2013.10.001","article-title":"Illuminating somatostatin analog action at neuroendocrine tumor receptors","volume":"34","author":"Reubi","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2015.0012","article-title":"Role of somatostatin analogues in the treatment of neuroendocrine tumors","volume":"13","author":"Narayanan","year":"2015","journal-title":"J. Natl. Comprehens. Cancer Network\u202f: JNCCN"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0315","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189167_bb0320","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189167_bb0325","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2967\/jnumed.115.163865","article-title":"Safety and efficacy of 68Ga-DOTATATE PET\/CT for diagnosis, staging, and treatment Management of Neuroendocrine Tumors","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl. Med.: Off. Publ., Soc. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an eastern cooperative oncology group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189167_bb0335","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189167_bb0340","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0345","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9637","key":"10.1016\/j.bbcan.2024.189167_bb0350","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189167_bb0355","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in Thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189167_bb0360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of Everolimus in patients with Thymoma and Thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189167_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891383","article-title":"A phase II study of buparlisib in relapsed or refractory thymomas","volume":"12","author":"Abu Zaid","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189167_bb0375","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/annonc\/mds147","article-title":"Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas","volume":"23","author":"Mimae","year":"2012","journal-title":"Ann. Oncol.\u202f: Off.J. Eur. Soc. Med. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189167_bb0380","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0385","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/13543780903055049","article-title":"Cixutumumab","volume":"18","author":"McKian","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0390","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189167_bb0395","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189167_bb0400","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189167_bb0405","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189167_bb0410","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/15548627.2015.1017192","article-title":"The role of STAT3 in autophagy","volume":"11","author":"You","year":"2015","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0415","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0420","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0425","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0430","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","article-title":"A phase 2 study of Palbociclib for recurrent or refractory advanced Thymic epithelial tumors (KCSG LU17-21)","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"23","key":"10.1016\/j.bbcan.2024.189167_bb0435","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.bbcan.2024.189167_bb0440","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0445","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0450","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with Pembrolizumab in early triple-negative breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0455","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the Thymus and mediastinum: what is new in Thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2024.189167_bb0460","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3390\/ijms23147864","article-title":"Unraveling the immune microenvironment of Thymic epithelial tumors: implications for autoimmunity and treatment","volume":"23","author":"Masaoutis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2003.09.001","article-title":"CD4+ CD8+ double positive (DP) T cells in health and disease","volume":"3","author":"Parel","year":"2004","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189167_bb0470","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3390\/biomedicines11102702","article-title":"Legend or truth: mature CD4+CD8+ double-positive T cells in the periphery in health and disease","volume":"11","author":"Hagen","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2024.189167_bb0475","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13000-014-0215-7","article-title":"Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors","volume":"9","author":"Omatsu","year":"2014","journal-title":"Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0480","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/ol.2011.383","article-title":"Fascin expression in dendritic cells and tumor epithelium in thymoma and thymic carcinoma","volume":"2","author":"Sato","year":"2011","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0485","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41416-022-01875-7","article-title":"Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome","volume":"127","author":"Bocchialini","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0490","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/cas.14409","article-title":"CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma","volume":"111","author":"Sato","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189167_bb0495","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-022-33170-7","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189167_bb0500","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.18632\/aging.204108","article-title":"A novel immune-related microRNA signature for prognosis of thymoma","volume":"14","author":"Wang","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.bbcan.2024.189167_bb0505","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"10302","key":"10.1016\/j.bbcan.2024.189167_bb0510","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0515","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189167_bb0520","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for Unresectable gastric or gastroesophageal junction Cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189167_bb0525","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189167_bb0530","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2020.04.038","article-title":"Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses","volume":"145","author":"Ishihara","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0535","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.athoracsur.2018.08.037","article-title":"Clinicopathologic features of Thymoma with the expression of programmed death ligand 1","volume":"107","author":"Hakiri","year":"2019","journal-title":"Ann. Thorac. Surg."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189167_bb0540","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and Intratumoral heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189167_bb0545","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Modern Pathol.\u202f:Off. J. United States Can. Acad. Pathol., Inc"},{"key":"10.1016\/j.bbcan.2024.189167_bb0550","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189167_bb0555","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0560","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6324","article-title":"Programmed cell death ligand 1 expression on immune cells and survival in patients with nonmetastatic head and neck Cancer: a systematic review and Meta-analysis","volume":"6","author":"Bla\u017eek","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189167_bb0565","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with Thymic carcinoma treated with Pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2024.189167_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100392","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell reports. Medicine"},{"key":"10.1016\/j.bbcan.2024.189167_bb0575","article-title":"Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: case report","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0580","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/ph15070889","article-title":"Good response of advanced Thymic carcinoma with low PD-L1 expression to chemotherapy plus Pembrolizumab as first-line therapy and to Pembrolizumab as maintenance therapy: a case report","volume":"15","author":"Nishii","year":"2022","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.bbcan.2024.189167_bb0585","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"issue":"10","key":"10.1016\/j.bbcan.2024.189167_bb0590","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189167_bb0595","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1002\/cam4.5357","article-title":"Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients","volume":"12","author":"Hao","year":"2023","journal-title":"Cancer Med."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189167_bb0600","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033550","article-title":"Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: a case report","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189167_bb0605","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.bbcan.2024.189167_bb0610","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.bbcan.2024.189167_bb0615","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis","volume":"180","author":"Remon","year":"2023","journal-title":"Eur. J. Cancer (Oxford, England: 1990)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T18:13:44Z","timestamp":1737569624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0304419X24000982"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189167","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymic epithelial tumor medical treatment: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189167"}}